UK Life Sciences had a barnstorming 2021 with investment volumes of £2.5bn. A closer look at these figures shows that a sizeable proportion of the, already dwindling, up and built stock has now been traded. This leaves the limited stock opportunities firmly centred around development or repurposing.
Is repurposing a swifter, more sustainable, way to satisfy the life sciences demand problem?
In the life sciences sector, we are now into the creation phase with growing development pipelines in the Oxford, Cambridge and London markets but very few schemes actually having broken ground.
Competition for the life sciences equivalent of Mayfair on the Monopoly board has seen unparalleled land value growth. Prime sites in Oxford and Cambridge have recently hit eye watering levels of £25m per acre for largely unconsented sites.
If the ever-growing investor demand is anything to go by then these levels will be at least sustained in 2022.
For more information on any of these topics, our expertise and knowledge in the sector, or to discuss a particular project, please do contact one of our team.
